KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $50,121.28 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now directly owns 278,855 shares in the company, valued at $2,738,356.10. The trade was a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $10.03 on Friday. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The firm’s 50-day simple moving average is $8.87 and its 200 day simple moving average is $10.41. The firm has a market cap of $495.68 million, a price-to-earnings ratio of -2.76 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. Sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $634,000. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares during the period. Barclays PLC raised its holdings in KalVista Pharmaceuticals by 418.5% in the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after buying an additional 54,257 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $2,084,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Bank of America began coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).